Evidence map›Paper›PMID 22105362›Full record

ArticleOncogene2012

PAK1 is a breast cancer oncogene that coordinately activates MAPK and MET signaling.

Y Shrestha, E J Schafer, J S Boehm, S R Thomas, F He, J Du, S Wang, J Barretina, B A Weir, J J Zhao and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Oncogene, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed, 1 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

104 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Role of the p21-Activated Kinase Family in Tumor Immunity.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. The direct effect of fibroblast growth factor 23 on vascular smooth muscle cell phenotype and function.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  18. Article
  19. Article
  20. Article

44 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Y ShresthaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
E J Schafer
J S Boehm
S R Thomas
F He
J Du
S Wang
J Barretina
B A Weir
J J Zhao
K Polyak
T R Golub
R Beroukhim
W C Hahn
Broad Institute · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USDana-Farber/Harvard Cancer Center · USHarvard University · US

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6M
Functional Annotation of Cancer Genomes: TCGA, Glioblastoma and Ovarian CancerRC2CA148268 · NCI · DANA-FARBER CANCER INST · PI CHIN, LYNDA, HAHN, WILLIAM C. · 2009 to 2012
$6.6M
Regulation and function of IKKe in breast cancer initiation and maintenanceR01CA130988 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2009 to 2018
$3.5M
Integrated genomic approaches to identify and validate cancer targetsR33CA128625 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2008 to 2010
$1.6M
NCI NIH HHS 5 P30 CA06516NCI NIH HHS P30 CA006516NCI NIH HHS R01 CA130988NCI NIH HHS R33 CA128625NCI NIH HHS RC2 CA148268
6 · The paper itself

Abstract

Activating mutations in the RAS family or BRAF frequently occur in many types of human cancers but are rarely detected in breast tumors. However, activation of the RAS-RAF-MEK-ERK MAPK pathway is commonly observed in human breast cancers, suggesting that other genetic alterations lead to activation of this signaling pathway. To identify breast cancer oncogenes that activate the MAPK pathway, we screened a library of human kinases for their ability to induce anchorage-independent growth in a derivative of immortalized human mammary epithelial cells (HMLE). We identified p21-activated kinase 1 (PAK1) as a kinase that permitted HMLE cells to form anchorage-independent colonies. PAK1 is amplified in several human cancer types, including 30--33% of breast tumor samples and cancer cell lines. The kinase activity of PAK1 is necessary for PAK1-induced transformation. Moreover, we show that PAK1 simultaneously activates MAPK and MET signaling; the latter via inhibition of merlin. Disruption of these activities inhibits PAK1-driven anchorage-independent growth. These observations establish PAK1 amplification as an alternative mechanism for MAPK activation in human breast cancer and credential PAK1 as a breast cancer oncogene that coordinately regulates multiple signaling pathways, the cooperation of which leads to malignant transformation.

Indexed as

OncogenesBreast NeoplasmsCell ProliferationCell Transformation, NeoplasticEnzyme ActivationGenome, HumanHumansMammary Glands, HumanMAP Kinase Signaling SystemMitogen-Activated Protein Kinasesp21-Activated KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-metMET protein, humanMitogen-Activated Protein Kinasesp21-Activated KinasesPAK1 protein, humanPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktProto-Oncogene Proteins c-met

Identifiers

PMID22105362
PMCPMC3291810
OpenAlexW2112318373

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.